2024新発 Evaluation (PF Gedatolisib inhibitors mTOR/PI3K dual the of クラブ
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF,POD24-Based prognostic signature enables personalized risk,POD24-Based prognostic signature enables personalized risk,A Phase 1B open-label study of gedatolisib (PF-05212384) in,LINCRNA00273 promotes cancer metastasis and its G-Quadruplex,商品の説明はありません